At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Neurobehavioral Substrates of Propranolol's Effects on Drug Cue Reactivity
In Brief
A Phase 4 clinical trial evaluating Propranolol and Placebo for Cigarette Smoking. Completed, enrolled 44 participants across 1 site.
Detailed Summary
The central objective of this project is to obtain proof-of-concept data demonstrating the effects of propranolol (a beta-adrenergic antagonist) on neurobiological responses to personal smoking environments and behavioral responses in a laboratory smoking behavior task. Human cigarette smokers (N = 50) will take photographs of locations where they do and do not smoke cigarettes. They will then be randomly assigned to receive either propranolol (40 mg) or placebo prior to completing: A) An MRI session assessing neural responses to personal smoking/non-smoking environments, standard smoking/non-smoking environments and proximal smoking/non-smoking cues; and B) A laboratory session examining smoking behavior in response to environmental cues.
Study Details
Timeline
Interventions
Participants will take one dose of Propranolol (40mg IR) on two separate occasions.
Participants will take one dose of Placebo on two separate occasions.